Skip to content
Medical Health Aged Care, Science

Pancreatic cancer research receives $8m philanthropic funding boost

WEHI 4 mins read
Caption: L-R: Dr Belinda Lee, Associate Professor Tracy Putoczki, Jane Hemstritch AO, Clara Kosasih. Credit: WEHI

An exceptional $8 million, 10-year philanthropic investment will spearhead new treatments for pancreatic cancer and create a new dedicated research centre at WEHI.


The centre, to be established thanks to an investment by Australian business leader and WEHI President Jane Hemstritch AO, aims to help close the significant survival gap between pancreatic cancer and other cancers.


The Hemstritch Centre of Excellence for Pancreatic Cancer Research will provide a leading team of scientists and clinicians with long-term funding to ask big research questions. They aim to make major progress in treating what is expected to be Australia’s second biggest cancer killer by 2030.


At a glance


·       An $8 million philanthropic investment by business leader and WEHI President Jane Hemstritch will establish the Hemstritch Centre of Excellence for Pancreatic Cancer Research at WEHI.

·       Just 11.5% of those diagnosed with pancreatic cancer survive five years beyond their diagnosis, and it is expected to be Australia’s second most lethal cancer by 2030.

·       The long-term funding will support a game-changing and patient-centred translational research platform. This will support the development of novel approaches, including new drugs which are urgently needed for a disease with few current treatment options.


A devastating disease 

Pancreatic cancer is a major cancer killer in Australia, with 3600 people dying from this disease each year.


Due to a lack of specific symptoms in the early stages, most patients are diagnosed with advanced stage cancer affecting nearby organs. More than half of people with pancreatic cancer die within the first six months of diagnosis and just 11.5% will survive five years.


Sustained research investment has significantly improved survival outcomes for other cancers, including skin, breast, prostate and many blood cancers, but the progress in pancreatic cancer has been slow.


It is hoped the $8 million, 10-year philanthropic investment will be a much-needed boost that accelerates WEHI-led research into pancreatic cancer, and helps close the survival gap with other cancers.


WEHI director Professor Ken Smith said research investment was critical, given the growing number of people being diagnosed with pancreatic cancer and the poor survival rates.


“This investment is cause for hope for people with this most devastating of diseases, and I commend Jane for her vision, passion and generosity,” said Prof Smith.


“Our team of scientists have the knowledge and drive to create real change in an area where it is so desperately needed, and the assurance of this long-term funding gives them the ability to chase the next pancreatic cancer breakthrough.”


Game-changing treatments


The funding will allow researchers to make significant headway with an ambitious 10-year program of research planned.


Associate Professor Tracy Putoczki, a laboratory head in WEHI’s Personalised Oncology division, is collecting patient tumour samples that will be used to help personalise treatment by determining which therapies are most likely to work for each patient.


Her research team is using a range of patient samples, including organoids: miniature tumours that are grown in the lab from patient biopsies, allowing researchers to test hundreds of drugs on each cancer, which was not previously possible.


“Time and money have allowed scientists to make exceptional gains in treating other cancers, like melanoma, which until recently was as devastating as pancreatic cancer, until the game-changing discovery of immune therapies,” said Assoc Prof Putoczki.


The funding will help her team develop an integrated, patient-focused, translational research platform to establish better treatment strategies and support the development of a pipeline of new drugs.


"This innovative platform is a game-changer. By integrating clinical and laboratory research onto the same platform, it enables more coordinated scientific research, to find the right interventions for each patient, when they need it,” said Assoc Prof Putoczki.


Learning from every patient


The funding will also support the expansion of the PURPLE Pancreatic Cancer Translational Registry led by consultant medical oncologist at WEHI Dr Belinda Lee, a large-scale database that tracks the treatment journey of over 4000 patients at 48 cancer centres across Australia, New Zealand and Singapore.


This first-of-its kind translational registry was established at WEHI in 2016 and enables de-identified clinical and research data to be used in multiple ways to help clinicians improve patient diagnosis and treatment.


The new funding will allow the PURPLE registry to investigate novel trial designs for pancreatic cancer, and to be expanded to include a portal that supports patients, including allowing them to be matched to clinical trial opportunities.


A lasting legacy


Jane Hemstritch understands the devastating impact of pancreatic cancer. Her late husband, Philip, died of the disease, two-and-a-half years after diagnosis. Years earlier Philip’s father, Reg, died of the disease on the day he was diagnosed.


The experience of watching Philip’s treatment led Hemstritch to become a strong advocate for personalised medicine.


She hopes the Hemstritch Centre of Excellence for Pancreatic Cancer Research will help people rapidly access new, individualised therapies, given pancreatic cancer patients generally have so little time.


“The research team includes clinician-scientists, which will speed up the application of their discoveries to patients,” Hemstritch said.


“WEHI is a world-class medical research institute, and like all others, requires funding from a range of sources to do its work, and I’m pleased to be in the privileged position of being able to provide support.”


The $8 million investment also includes funding for a new pancreatic cancer research collaboration between WEHI and the Garvan Institute of Medical Research in NSW, part of a broader network of clinicians and scientists working together to improve outcomes for pancreatic cancer patients.


While the investment provides a substantial start for the research team, further funding will be needed for the centre to expand its program and to meet its ambitious aims.


Hemstritch said long term philanthropic investment helps researchers focus on their science, freeing up time that would otherwise be spent applying for grants, and allowing a longer-term view.


“Finding effective therapies for this most dreadful of cancers is critically important, so we need to set researchers up so they can make a concentrated effort over the long term – philanthropy is critical to achieving this,” she said.



Images and captions for publication are available at this link:

About us:


About WEHI (Walter and Eliza Hall Institute of Medical Research)

WEHI is where the world’s brightest minds collaborate and innovate to make life-changing scientific discoveries that help people live healthier for longer. Our medical researchers have been serving the community for more than 100 years, making transformative discoveries in cancers, infectious and immune diseases, developmental disorders, and healthy ageing. WEHI brings together diverse and creative people with different experience and expertise to solve some of the world’s most complex health problems. With partners across science, health, government, industry, and philanthropy, we are committed to long-term discovery, collaboration, and translation. At WEHI, we are brighter together.   
Find out more at


Contact details:

M: +61 475 751 811 



More from this category

  • Medical Health Aged Care
  • 24/06/2024
  • 17:07
Takeda Pharmaceutical Company Limited

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1 CMV Is One of the Most Common…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 24/06/2024
  • 16:20
National Rural Health Alliance

Community-led innovation to revolutionise healthcare access in rural Australia

The National Rural Health Alliance (the Alliance) is delighted that the Minister for Health and Aged Care, the Hon Mark Butler, has today announced…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 24/06/2024
  • 12:25
Jane Morgan Management

Imugene (ASX:IMU) Doses First Patient in Pioneering Phase 1 onCARlytics Trial

Sydney, Australia, 24 June 2024: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is thrilled to announce the dosing of the first patient in the intravenous (IV) infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial. This groundbreaking trial, named OASIS, is being conducted at City of Hope in California and is designed to transform the treatment landscape for patients with advanced solid tumors. The OASIS trial is a world-first, combining a CD19-expressing oncolytic virus with a CD19-targeting drug. The trial aims to recruit 40-45 patients with advanced solid cancers that have metastasized, with preliminary early combination data…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.